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Primary IgA nephropathy (IgAN) is a common glomerular
disease with a complex genetic architecture. Ethnic differ-
ences in susceptibility to IgAN, as well as inter-individual
variation in the disease course and prognosis strongly argue
for the crucial role of genetic factors in its pathogenesis. For
example, IgAN occurs with greatest frequency in Chinese
and Japanese populations but is relatively rare in individu-
als of African descent [1]. A high frequency of IgAN has
also been reported in biopsies of Zuni and Manitoba Na-
tive Americans and Australian aborigines [2–6]. Familial
aggregation of IgAN was first reported in the 1970s, and
multiple large series of familial cases have provided further
evidence for genetic contribution. Two European studies
demonstrated that 4–10% of patients with IgAN had a fam-
ily history of kidney disease [7,8]. In other studies, urinary
abnormalities were detected in over 20% of asymptomatic
first degree relatives of IgAN patients [9]. Several extended
kindreds with IgAN have also been reported throughout the
world, including the United States [10], France [11], Italy
[12], Canada [13], Australia [5] and Lebanon [14]. In all
reported families, segregation of IgAN is consistent with
autosomal dominant transmission with incomplete pene-
trance, although more complex genetic models are also
compatible with the observed pedigrees. The incomplete
penetrance is likely explained by the requirement of addi-
tional environmental or genetic factors for clinical mani-
festation of disease.
To date, three genome-wide linkage studies of familial
IgAN have been reported, but no causal gene has yet been
identified [13,15,16]. Unfortunately, numerous difficulties
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hinder linkage studies of familial IgAN. Foremost, familial
forms are under-recognized, since the associated urinary ab-
normalities are often mild or intermittent in affected family
members. Most prohibitive is the lack of a reliable non-
invasive screening test for IgAN. Currently, the unaffected
status is difficult to confirm because renal biopsy carries
too many risks to be performed on all family members.
As a result, linkage studies are often limited by the use
of less accurate phenotypes (such as microscopic haema-
turia) or affected-only analyses. Both of these approaches
result in decreased power to detect linkage. Additionally,
microscopic haematuria is relatively common in the gen-
eral population, thus phenotype misclassification can oc-
cur rather easily in the absence of kidney biopsy. Finally,
considering significant variability in the clinico-pathologic
features of IgAN, it is likely that this diagnosis encompasses
several disease subsets. Presently, there is no good way to
distinguish such subsets, although the recently proposed
Oxford classification of IgAN, as well as ongoing research
in the area of IgAN biomarker discovery may offer some
help in this respect [17]. From the statistical perspective,
heterogeneity is of primary concern when many small pedi-
grees are analysed jointly. In this situation, increasing the
sample size of a linkage study by inclusion of new fami-
lies may, paradoxically, lead to decreased power. One way
to circumvent this issue is to study large multiplex fami-
lies; however, this approach poses multiple computational
challenges, and large families are more difficult to ascer-
tain. Similarly, large genealogies reported from Kentucky
or Italy, while clearly demonstrating genetic contribution to
the IgAN, are not tractable to linkage methods. Many can-
didate genes have been suggested, but nearly all published
genetic association studies suffer from small sample size,
inadequate correction for population stratification and lack
of independent replication [18]. In addition, many of the
studies focus on IgAN progression rather than causality.
Most importantly, however, our limited understanding of
the disease pathogenesis restricts the choices of plausible
candidate genes. Hence, further progress in the genetics of
IgAN will require application of genome-wide association
studies in large cases and controls cohorts.
Despite the above challenges, rapid progress in the
field of genomics combined with recent advances in the
IgAN biomarker research is likely to accelerate gene-
identification efforts. Particularly, the development of a
reliable IgAN biomarker would enable diagnosis without
the requirement of kidney biopsy and greatly facilitate
family screening in linkage studies. In this area, the most
promising are studies of the glycosylation defects of IgA1,
a subclass of IgA present in serum and mesangial deposits
of IgAN patients. In healthy individuals, the hinge region
of IgA1 contains up to 6 O-linked glycans, composed of
N-acetyl-galactosamine (GalNAc) with beta-1,3-linked
galactose, both of which can be sialylated. In IgAN patients,
a significant portion of the circulating IgA1 is galactose-
deficient (Gd-IgA1). Galactose-deficient O-linked glycans
of IgA1 are potentially antigenic and may promote forma-
tion of immune complexes when recognized by naturally oc-
curring anti-glycan antibodies in the circulation [19]. Sub-
sequent mesangial deposition of immune complexes con-
taining Gd-IgA1 is likely responsible for glomerular injury.
Interestingly, galactose deficiency appears to be specific to
IgA1 molecules, and it is absent in other glycoproteins, such
as IgD, in the same patients [20]. Therefore, it is most likely
that the IgA1 glycosylation defect arises secondary to aber-
rant immunoregulation or disruption within the specific
subpopulation of B-cells that produce IgA1. The molecular
mechanisms involved in the development and regulation of
IgA1-secreting cells remain to be elucidated.
Recently, a reliable lectin-based ELISA assay for deter-
mination of serum Gd-IgA1 has been developed. This as-
say utilizes a naturally occurring lectin derived from Helix
aspersa snail to detect galactose-deficient O-linked gly-
cans in the circulation. In a Caucasian population from the
southeastern USA, this test had 90% specificity and 76%
sensitivity to diagnose sporadic IgAN [21]. Although this
assay will need to be standardized and validated in more
diverse populations, it appears to be extremely promising
as a new non-invasive diagnostic test for IgAN. Moreover,
this assay facilitates genetic studies that seek to identify
genes involved in defective glycosylation of IgA1.
The first strong evidence that IgA1 glycosylation de-
fects may be inherited came from a study examining serum
Gd-IgA1 levels in a large cohort of IgAN cases and their
relatives [22]. The heritability or the proportion of variation
in Gd-IgA1 that is attributable to genetic factors was highly
significant and estimated at 54%. A clear cosegregation of
high Gd-IgA1 levels and IgAN phenotype was observed
in the pedigrees with familial disease. Moreover, Gd-IgA1
levels were significantly higher among relatives at risk for
IgAN under autosomal dominant transmission compared to
controls or individuals who married into the families. Sim-
ilar observations have recently been reported in a smaller
cohort of Chinese patients with sporadic IgAN [23], as well
as in a group of paediatric cases of IgAN with Henoch–
Scho¨nlein purpura (R. Wyatt, unpublished observations).
Interestingly, among individuals with sporadic IgAN, two
distinct subgroups have emerged. The index cases with high
Gd-IgA1 (majority of cases) had relatives with predomi-
nantly high Gd-IgA1. However, the index cases with low
Gd-IgA1 levels had relatives with levels that were indis-
tinguishable from healthy controls. In addition, there were
many relatives of IgAN patients who had high Gd-IgA1,
yet they lacked any signs of kidney disease. Taken together,
it appears that Gd-IgA1 is neither required nor sufficient to
cause the clinical disease. Rather, it should be considered
as one of the quantitative risk factors for IgAN, a situa-
tion that may be analogous to a serum cholesterol level
in the risk of coronary artery disease. Additional cofac-
tors including other genetic or environmental triggers are
likely required for full disease manifestation. For example,
a recent study suggests that the individual’s propensity to
develop anti-glycan antibodies that promote immune com-
plex formation with Gd-IgA1 may represent one of such
cofactors [24].
The above data suggest that stratification by Gd-IgA1
may be used to define subpopulations of IgAN patients
with distinct disease pathogenesis. This information can
be used to reduce heterogeneity in genetic studies, thus
enhance their power to detect novel susceptibility loci. The
Gd-IgA1 level can also be used as a quantitative endopheno-
type in linkage and genetic association studies. Quantitative
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endophenotypes are frequently preferred in the genetic
studies of a complex disease, since they may be a closer
reflection of a specific underlying pathogenic process. Fur-
thermore, analysis of quantitative traits typically provides
greater power compared to discrete trait. A similar approach
has been successful in genetic studies of serum LDL to
map the genes responsible for dyslipidaemia [25,26] or
serum IgE levels to map novel susceptibility loci for asthma
[27,28]. Lastly, joint genetic analyses of Gd-IgA1 and IgAN
phenotypes may enable identification of mediators and co-
factors in the pathway leading to renal injury. Integration of
quantitative phenotype–genotype correlations and genome-
wide gene expression profiles of IgA1-secreting cells may
also be helpful in elucidating pathogenic pathways. The
declining cost of high throughput genotyping, improved
quality of gene expression microarrays and the existence of
robust statistical methods for the analysis of genome-wide
data will facilitate these types of studies.
In summary, serum level of Gd-IgA1 defines a new en-
dophenotype that is highly inherited and closely linked to
IgAN pathogenesis. Quantitative genetic studies of Gd-
IgA1 are likely to be more powerful than linkage stud-
ies base on clinical phenotypes. In addition, profiling cases
based on Gd-IgA1 level may help to identify case subgroups
with distinct disease aetiologies, thus reducing heterogene-
ity in linkage and genetic association studies of IgAN. In
the subset of IgAN cases with high levels of Gd-IgA1, the
inciting genetic defect is likely to reside within the com-
plex immunoregulatory pathways that control IgA1 syn-
thesis and its post-translational modification. Finally, in the
face of phenotypic complexity of IgAN, large cohorts and
considerable international collaboration will be needed to
perform adequately powered genome-wide studies of Gd-
IgA1 and IgAN.
Acknowledgements. K.K. is supported by the Daland Fellowship from
the American Philosophical Society and grant number KL2 RR024157
from the National Center for Research Resources (NCRR), a compo-
nent of the National Institutes of Health (NIH) and NIH Roadmap for
Medical Research. A.G. Gharavi and F.S. are supported by grant number
1R01DK082753-01 from the National Institute of Diabetes and Diges-
tive and Kidney Diseases (NIDDK). The contents of this publication are
solely the responsibility of the authors and do not necessarily represent
the official view of NCRR, NIDDK or NIH.
Conflict of interest statement: None declared.
References
1. Hall YN, Fuentes EF, Chertow GM et al. Race/ethnicity and disease
severity in IgA nephropathy. BMC Nephrol 2004; 5: 10
2. Hoy WE, Hughson MD, Smith SM et al. Mesangial proliferative
glomerulonephritis in southwestern American Indians. Am J Kidney
Dis 1993; 21: 486–496
3. Smith SM, Harford AM. IgA nephropathy in renal allografts: in-
creased frequency in native American patients. Ren Fail 1995; 17:
449–456
4. Hughson MD, Megill DM, Smith SM et al. Mesangiopathic glomeru-
lonephritis in Zuni (New Mexico) Indians.Arch Pathol LabMed 1989;
113: 148–157
5. O’Connell PJ, Ibels LS, Thomas MA et al. Familial IgA nephropathy:
a study of renal disease in an Australian aboriginal family. Aust NZ J
Med 1987; 17: 27–33
6. Casiro OG, Stanwick RS, Walker RD. The prevalence of IgA
nephropathy in Manitoba Native Indian children. Can J Public Health
1988; 79: 308–310
7. Johnston PA, Brown JS, Braumholtz DA et al. Clinico-pathological
correlations and long-term follow-up of 253 United Kingdom patients
with IgA nephropathy. A report from the MRC Glomerulonephritis
Registry. Q J Med 1992; 84: 619–627
8. Rambausek M, Hartz G, Waldherr R et al. Familial glomerulonephri-
tis. Pediatr Nephrol (Berlin, Germany) 1987; 1: 416–418
9. Schena FP, Scivittaro V, Ranieri E et al. Abnormalities of the IgA
immune system in members of unrelated pedigrees from patients with
IgA nephropathy. Clin Exp Immunol 1993; 92: 139–144
10. Julian BA, Quiggins PA, Thompson JS et al. Familial IgA nephropathy.
Evidence of an inherited mechanism of disease. N Engl J Med 1985;
312: 202–208
11. Levy M. Familial cases of Berger’s disease and anaphylactoid purpura:
more frequent than previously thought. Am J Med 1989; 87: 246–248
12. Scolari F, Amoroso A, Savoldi S et al. Familial clustering of IgA
nephropathy: further evidence in an Italian population. Am J Kidney
Dis 1999; 33: 857–865
13. Paterson AD, Liu XQ, Wang K et al. Genome-wide linkage scan of
a large family with IgA nephropathy localizes a novel susceptibil-
ity locus to chromosome 2q36. J Am Soc Nephrol 2007; 18: 2408–
2415
14. Karnib HH, Sanna-Cherchi S, Zalloua PA et al. Characterization of
a large Lebanese family segregating IgA nephropathy. Nephrol Dial
Transplant 2007; 22: 772–777
15. Gharavi AG, Yan Y, Scolari F et al. IgA nephropathy, the most com-
mon cause of glomerulonephritis, is linked to 6q22–23. Nat Genet
2000; 26: 354–357
16. Bisceglia L, Cerullo G, Forabosco P et al. Genetic heterogeneity in
Italian families with IgA nephropathy: suggestive linkage for two
novel IgA nephropathy loci. Am J Hum Genet 2006; 79: 1130–
1134
17. Cattran DC, Coppo R, Cook HT et al. The Oxford classification
of IgA nephropathy: rationale, clinicopathological correlations, and
classification. Kidney Int 2009
18. Beerman I, Novak J, Wyatt RJ et al. The genetics of IgA nephropathy.
Nat Clin Pract Nephrol 2007; 3: 325–338
19. Tomana M, Novak J, Julian BA et al. Circulating immune com-
plexes in IgA nephropathy consist of IgA1 with galactose-deficient
hinge region and antiglycan antibodies. J Clin Invest 1999; 104: 73–
81
20. Smith AC, de Wolff JF, Molyneux K et al. O-glycosylation of serum
IgD in IgA nephropathy. J Am Soc Nephrol 2006; 17: 1192–1199
21. Moldoveanu Z, Wyatt RJ, Lee JY et al. Patients with IgA nephropa-
thy have increased serum galactose-deficient IgA1 levels. Kidney Int
2007; 71: 1148–1154
22. Gharavi AG, Moldoveanu Z, Wyatt RJ et al. Aberrant IgA1 glycosy-
lation is inherited in familial and sporadic IgA nephropathy. J Am Soc
Nephrol 2008; 19: 1008–1014
23. Lin X, Ding J, Zhu L et al. Aberrant galactosylation of IgA1 is involved
in the genetic susceptibility of Chinese patients with IgA nephropathy.
Nephrol Dial Transplant 2009
24. Suzuki H, Fan R, Zhang Z et al. Aberrantly glycosylated IgA1 in IgA
nephropathy patients is recognized by IgG antibodies with restricted
heterogeneity. J Clin Invest 2009; 119: 1668–1677
25. Kathiresan S, Melander O, Guiducci C et al. Six new loci associated
with blood low-density lipoprotein cholesterol, high-density lipopro-
tein cholesterol or triglycerides in humans. Nat Genet 2008; 40: 189–
197
26. Kathiresan S, Willer CJ, Peloso GM et al. Common variants at 30 loci
contribute to polygenic dyslipidemia. Nat Gen 2009; 41: 56–65
27. Weidinger S, Gieger C, Rodriguez E et al. Genome-wide scan on total
serum IgE levels identifies FCER1A as novel susceptibility locus.
PLoS Genet 2008; 4: e1000166
28. Denham S, Koppelman GH, Blakey J et al. Meta-analysis of genome-
wide linkage studies of asthma and related traits. Respir Res 2008; 9:
38
Received for publication: 12.9.09; Accepted in revised form: 14.10.09
 at U
niversita of Brescia on O
ctober 23, 2012
http://ndt.oxfordjournals.org/
D
ow
nloaded from
 
